**Specifications Table**TableSubject area*Proteomics*More specific subject area*Clinical chemistry, Biomarker analysis, Blood proteome profiling*Type of data*Tables, figures (PDF file format)*How data was acquired*nano liquid chromatography (AQUITY UPLC M-CLASS, Waters Corporation) tandem mass spectrometry (Synapt G2Si mass spectrometer, WATERS Corporation)UDMS*^*E*^*data acquisition*Data format*Analyzed and processed data*Experimental factors*24 blood samples were drawn from 6 healthy young volunteers in serum tubes and plasma tubes containing EDTA, heparin, and citrate.*Experimental features*Serum and plasma was obtained after tube manufacturer\'s instructions and aliquots were stored at -80  °C until analysis. Protein profiles were analyzed before and after samples depletion of 6 high abundant proteins using a commercial MARS6 (Agilent Technologies) immunoaffinity based column. Prior to the mass spectrometric analysis, proteins were digested by trypsin and peptides were further analyzed and protein profiles investigated with respect to the sample collection method influence.*Data source location*Greifswald, Germany*Data accessibility*Data is with article*

**Value of the data**•Data shows a comprehensive evaluation of the different blood sample collection methods on 6 high abundant proteins and their depletion efficiency using immunoaffinity MARS6 column which can be used for future investigations on blood high abundant proteins and depleted fractions.•Individual protein abundances, their presence and variance in the samples collected with different methods after depletion are of potential value to determine which sampling method to be used for proteomics investigations.•Data presents an all-inclusive set of information on the methods applied to evaluate the impact of different blood sample collection methods on protein profiling studies and can be used as benchmark for future blood protein profiling studies.

1. Data {#s0005}
=======

In this Data in Brief article we provide detailed information on blood protein profiling as an extension of the results reported in Ref. [@bib1], 24 blood specimens were collected from 6 healthy and young volunteers in different sample collection tubes for serum and plasma. Tubes characteristics and the subsequent sample preparation are presented in [Table 1](#t0005){ref-type="table"}. For the blood protein profiling a nanoLC-UDMS^E^ method and standard search parameters were employed. Detailed description of methods can be found in Ref. [@bib1] and its supplementary methods. 6 highly abundant blood proteins, namely serum albumin, immunoglobulin gamma, immunoglobulin alpha, serotransferrin, haptoglobin, and alpha-1-antitrypsin, were depleted by using a commercially available immunoaffinity depletion column. A detailed overview on depletion efficiency based on protein abundances for all sample collection methods is presented in [Table 2](#t0010){ref-type="table"}. The distribution of the high abundant proteins before and after depletion is presented in [Fig. 1](#f0005){ref-type="fig"} and more specific, fibrinogen coverage is shown in [Fig. 2](#f0010){ref-type="fig"}. Data regarding number of identified peptides and relatively quantified proteins for all sample types after depletion is shown in [Fig. 3](#f0015){ref-type="fig"}. Also, a top 10 list of the most abundant unique proteins for each of the EDTA-, heparin-, citrate plasma and serum samples is given in [Table 3](#t0015){ref-type="table"}. The complete list of all relatively quantified proteins over all samples including their occurrence in the protein core set or as unique proteins interpreted in detail previously [@bib1], can be found in the Supplementary material with data on individual sample abundance, mean abundance for each sample collection method and the abundance based coefficient of variation after depletion.Fig. 1HAP abundance before and after depletion.Fig. 1Fig. 2Total fibrinogen abundance before and after depletion of HAP.Fig. 2Fig. 3Global overview on the identified peptides and quantified proteins.Fig. 3Table 1Blood sample collection tubes characteristics.Table 1**Blood productSerumPlasmaTube type**Plastic SST™ II AdvancePlastic K2EDTAGlass CitrateGlass sodium heparin**Cat. No./NHS code**367954/KFK114367873/KFK286367691/KFK186367876/KFK279**Additive (concentration)**Silica (clot activator)/gelPotassium EDTABuffered sodium citrate (0,105 M)Sodium heparin (17 IU/mL blood)**Volume (mL)**564.56**Mixing recommendation**Gently inverted 180° and backGently inverted 180° and backGently inverted 180° and backGently inverted 180° and back5--6 times8--10 times3--4 times8--10 timesTable 2Summary of depletion efficiency.Table 2Mean protein abundance**EDTA plasmaHeparin plasmaCitrate plasmaSerum**Before depletionAfter depletionBefore depletionAfter depletionBefore depletionAfter depletionBefore depletionAfter depletionAll proteins40568018.7444741390.0435119594.0752949084.1740671622.4069872,370.9054995897.8945191163.47α-1-antitrypsin757196.3414259.97584561.1723153.90764890.5722854.171006489.6529692.67Haptoglobin631767.3918029.34487822.5841219.67596917.7956161.72689948.1941259.85Ig A429327.8944422.15380247.3323957.12431941.1251775.29550978.4618885.19Ig G 1--42013660.8691452.631677118.63101491.822145431.99168092.782856603.51124679.28Serotransferrin2369837.17213742.012096978.58183333.162651548.54364344.323224215.08202618.47Serum albumin15235797.332056072.7512925303.831866019.8115394810.673600066.3322315530.672807855.77Other proteins19130431.7642303411.1916967561.9450709908.6918686081.7265609076.2924352132.3341966172.25Total fibrinogen1839721.657325737.501108301.526370617.461657777.209817167.880.0071699.88Table 3TOP 10 abundant proteins exclusively identified per sampling method.**AccessionEntry nameTOP10_EDTA plasma Protein namesSecreted/ leakageEDTA 1EDTA2EDTA3EDTA4EDTA5EDTA6MeanCV**[O75410](ncbi-p:O75410){#ir0005}TACC1Transforming acidic coiled-coil-containing protein 1Leakage4917465077109984542296583339035638890.39[Q9P2D6](ncbi-p:Q9P2D6){#ir0010}F135AProtein FAM135ANot specified47425511409049330845791546010407700.43[Q99683](ncbi-p:Q99683){#ir0015}M3K5Mitogen-activated protein kinase kinase kinase 5leakage375584489334790368565233337776407010.16[Q9P0W8](ncbi-p:Q9P0W8){#ir0020}SPAT7Spermatogenesis-associated protein 7Leakage216403286628811179383273219729256190.26[Q9BYW2](ncbi-p:Q9BYW2){#ir0025}SETD2Histone-lysine N-methyltransferase SETD2Leakage220272658321030225613093120783239860.17[Q15573](ncbi-p:Q15573){#ir0030}TAF1ATATA box-binding protein-associated factor RNA polymerase I subunit ALeakage146712007822199210652735918243206030.21[P15813](ncbi-p:P15813){#ir0035}CD1DAntigen-presenting glycoprotein CD1dLeakage133951728013398140712092315275157240.19[O14950](ncbi-p:O14950){#ir0040}ML12BMyosin regulatory light chain 12BNot specified105089974117841329187539291106000.16[Q5TBE3](ncbi-p:Q5TBE3){#ir0045}CI153Uncharacterized protein C9orf153Not specified618376398439754311014712879910.21[Q8N4P6](ncbi-p:Q8N4P6){#ir0050}LRC71Leucine-rich repeat-containing protein 71Not specified104638450570371236758686975610.22**AccessionEntry nameTOP10_heparin plasma Protein namesSecreted/ leakageHeparin1Heparin2Heparin3Heparin4Heparin5Heparin6MeanCV**[Q8WUY3](ncbi-p:Q8WUY3){#ir0055}PRUN2Protein prune homolog 2Leakage1607232062881925733062942471582834872327540.24[Q15811](ncbi-p:Q15811){#ir0060}ITSN1Intersectin-1Leakage509596310053081482209043134339566880.33[Q00610](ncbi-p:Q00610){#ir0065}CLH1Clathrin heavy chain 1Leakage155861472818562208152293520262188150.17[P24043](ncbi-p:P24043){#ir0070}LAMA2Laminin subunit alpha-2Secreted113921228814534176881661015376146480.17[Q96RE9](ncbi-p:Q96RE9){#ir0075}ZN300Zinc finger protein 300Leakage71341136511937200511503315472134990.33[Q9P0W5](ncbi-p:Q9P0W5){#ir0080}SCHI1Schwannomin-interacting protein 1Leakage170221027310231140511071010656121570.23[Q5RL73](ncbi-p:Q5RL73){#ir0085}RBM48RNA-binding protein 48Not specified545484241153114460890621118116490.48[Q9P219](ncbi-p:Q9P219){#ir0090}DAPLEProtein DapleLeakage71621020014709108571118310820108220.22[Q8N3R3](ncbi-p:Q8N3R3){#ir0095}TCAIMT-cell activation inhibitor, mitochondrialLeakage1313811101896586229601805799140.19[Q7LG56](ncbi-p:Q7LG56){#ir0100}RIR2BRibonucleoside-diphosphate reductase subunit M2 BLeakage545281098708102508552923583840.19**AccessionEntry nameTOP10_citrate plasma Protein namesSecreted/ leakageCitrate1Citrate2Citrate3Citrate4Citrate5Citrate6MeanCV**[Q9P2M7](ncbi-p:Q9P2M7){#ir0105}CINGCingulinLeakage254222000321886235463096124534243920.15[P12259](ncbi-p:P12259){#ir0110}FA5Coagulation factor VSecreted238141793319660257521838925697218740.17[Q9P2F6](ncbi-p:Q9P2F6){#ir0115}RHG20Rho GTPase-activating protein 20Not specified235892200716027128552789620017203980.26[Q8N4C7](ncbi-p:Q8N4C7){#ir0120}STX19Syntaxin-19Leakage288542045115902130992299913806191850.32[P01036](ncbi-p:P01036){#ir0125}CYTSCystatin-Ssecreted111011565913394135861200313467132010.12[Q9UHR6](ncbi-p:Q9UHR6){#ir0130}ZNHI2Zinc finger HIT domain-containing protein 2Not specified1944316822496739131058111941112780.55[Q96RG2](ncbi-p:Q96RG2){#ir0135}PASKPAS domain-containing serine/threonine-protein kinaseLeakage64795955874969069560720774760.19[P82970](ncbi-p:P82970){#ir0140}HMGN5High mobility group nucleosome-binding domain-containing protein 5Leakage95488133729568107588510374130.20[Q9Y275](ncbi-p:Q9Y275){#ir0145}TN13BTumor necrosis factor ligand superfamily member 13BSecreted75605901955282305887501370240.24[Q8TBF8](ncbi-p:Q8TBF8){#ir0150}FA81AProtein FAM81ANot specified239714042487966855055628765580.60**AccessionEntry nameTOP10_serum Protein namesSecreted/ leakageSerum 1Serum2Serum3Serum4Serum5Serum6MeanCV**[P04275](ncbi-p:P04275){#ir0155}VWFvon Willebrand factorSecreted1712962027391925981668701838331870441840630.07[O95602](ncbi-p:O95602){#ir0160}RPA1DNA-directed RNA polymerase I subunit RPA1Leakage1188171769261840071922321452881776921658270.17[Q9ULI0](ncbi-p:Q9ULI0){#ir0165}ATD2BATPase family AAA domain-containing protein 2BLeakage519356455722306532826225557282519360.30[Q96HQ0](ncbi-p:Q96HQ0){#ir0170}ZN419Zinc finger protein 419Leakage364265032048458364005431839176441830.18[P07996](ncbi-p:P07996){#ir0175}TSP1Thrombospondin-1Leakage443673943321407423694786737343387970.24[Q9BS31](ncbi-p:Q9BS31){#ir0180}ZN649Zinc finger protein 649Leakage238934150727030514433705643081373350.28[A6NET4](ncbi-p:A6NET4){#ir0185}OR5K3Olfactory receptor 5K3Leakage382303744843819305732530333517348150.19[Q8WXX0](ncbi-p:Q8WXX0){#ir0190}DYH7Dynein heavy chain 7, axonemalLeakage191532632019664220163303719816233340.23[Q7Z443](ncbi-p:Q7Z443){#ir0195}PK1L3Polycystic kidney disease protein 1-like 3Leakage1259775421965427879143514420144070.59[P98196](ncbi-p:P98196){#ir0200}AT11AProbable phospholipid-transporting ATPase IHLeakage156471030712192156341415217414142240.18

2. Experimental design, materials and methods {#s0010}
=============================================

Experimental design and the materials and methods have been reported previously [@bib1].

Transparency document. Supporting information {#s0021}
=============================================

Supplementary material.

Appendix A. Supplementary material {#s0020}
==================================

Overview on all sample collection methods relatively quantified proteins after depletion.
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